GlassScriptPhysician profile
Kyle Allan Kenobbie
NPI 1316642234
$4,850.77
in general payments reported to CMS, 2019-2025
49 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $910 · 2024: $1,973 · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,592 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,591.79 |
| Education | $258.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $524.27 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $457.77 | 2024-2025 | Enhertu, Imfinzi, Lynparza |
| Regeneron Healthcare Solutions, INC. | $378.37 | 2023-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $295.05 | 2023-2025 | Keytruda, Keytruda Qlex, Welireg |
| Novartis Pharmaceuticals Corporation | $288.36 | 2023-2025 | |
| Daiichi Sankyo INC. | $273.81 | 2023-2025 | Enhertu, Datroway |
| Sobi, INC | $220.70 | 2023-2024 | |
| Pfizer INC. | $178.09 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.38 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Genzyme Corporation | $143.74 | 2024-2025 | |
| Eisai INC. | $125.69 | 2023-2025 | |
| Genentech, INC. | $102.70 | 2024 | Tecentriq |
| Jazz Pharmaceuticals INC. | $99.44 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $95.67 | 2023-2025 | Ojjaara, Jemperli, Zejula |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $95.42 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Stemline Therapeutics INC. | $88.98 | 2023-2025 | Orserdu |
| Blueprint Medicines Corporation | $83.35 | 2023-2025 | Ayvakit |
| Legend Biotech USA INC. | $76.34 | 2024-2025 | Carvykti |
| Acrotech Biopharma INC. | $70.65 | 2024-2025 | Beleodaq, Ryzneuta |
| Abbvie INC. | $68.34 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $66.34 | 2023-2024 | Ultomiris |
| Beone Medicines USA, INC. | $64.14 | 2025 | Tevimbra |
| Genentech USA, INC. | $61.40 | 2024-2025 | Alecensa, Tecentriq, Phesgo |
| Servier Pharmaceuticals LLC | $55.82 | 2023-2025 | |
| Tersera Therapeutics LLC | $54.46 | 2024 | Zoladex, Xermelo |
| Janssen Biotech, INC. | $53.97 | 2023-2025 | Darzalex, Imbruvica |
| Karyopharm Therapeutics INC. | $52.59 | 2023-2024 | Xpovio |
| Astellas Pharma US INC | $48.59 | 2025 | Vyloy, Xospata |
| Seagen INC. | $39.71 | 2023 | Padcev, Adcetris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.27 | 2023 | Gilotrif |
| Sumitomo Pharma America, INC. | $32.24 | 2024-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $31.45 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $29.37 | 2025 | Yescarta |
| Pharmaessentia USA Corporation | $24.98 | 2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $24.98 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Kyowa Kirin, INC. | $24.35 | 2025 | |
| Puma Biotechnology, INC. | $24.01 | 2025 | |
| Foundation Medicine, INC. | $23.40 | 2023 | |
| Coherus Oncology, INC. | $23.23 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $21.41 | 2024 | Onivyde |
| Emd Serono, INC. | $21.33 | 2024 | |
| Beigene USA, INC. | $20.20 | 2025 | Tevimbra |
| Deciphera Pharmaceuticals INC. | $20.01 | 2025 | Romvimza, Qinlock |
| Incyte Corporation | $17.70 | 2025 | Monjuvi, Zynyz |
| Agios Pharmaceuticals, INC. | $17.14 | 2023 | Pyrukynd |
| Exelixis INC. | $17.06 | 2024 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $16.91 | 2023 | Fotivda |
| Array Biopharma INC | $16.91 | 2025 | Braftovi, Mektovi, Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Kenobbie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.